US Pharma MarketingFDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis
The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients.
The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis
Source: Endpoints News